Prognostic value of interleukin-1 receptor antagonist gene polymorphism and cytomegalovirus seroprevalence in patients with coronary artery disease by Rothenbacher, Dietrich et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Prognostic value of interleukin-1 receptor antagonist gene 
polymorphism and cytomegalovirus seroprevalence in patients with 
coronary artery disease
Dietrich Rothenbacher1, Hermann Brenner1, Thomas Mertens2, 
Michael M Hoffmann3, Albrecht Hoffmeister4 and Wolfgang Koenig*4
Address: 1Department of Epidemiology, The German Centre for Research on Ageing, University of Heidelberg, Germany, 2Department of Virology, 
University of Ulm, Ulm, Germany, 3Department of Clinical Chemistry, University of Freiburg, Freiburg, Germany and 4Department of Internal 
Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
Email: Dietrich Rothenbacher - rothenbacher@dzfa.uni-heidelberg.de; Hermann Brenner - brenner@dzfa.uni-heidelberg.de; 
Thomas Mertens - thomas.mertens@medizin.uni-ulm.de; Michael M Hoffmann - mhoff@med1.ukl.uni-freiburg.de; 
Albrecht Hoffmeister - albrecht.hoffmeister@medizin.uni-ulm.de; Wolfgang Koenig* - wolfgang.koenig@medizin.uni-ulm.de
* Corresponding author    
Abstract
Background: Chronic inflammatory stimuli such as cytomegalovirus (CMV) infection and various
genetic polymorphisms determining the inflammatory response are assumed to be important risk
factors in atherosclerosis. We investigated whether patients with stable coronary artery disease
(CAD) and homozygous for allele 2 of the interleukin 1 receptor antagonist (IL-1RA) gene and
seropositive for CMV represent a group particular susceptible for recurrent cardiovascular events.
Methods: In a series of 300 consecutive patients with angiographically defined CAD a prospective
follow-up was conducted (mean age 57.9 years, median follow-up time 38.2 months).
Results: No statistically significant relationship was found between CMV serostatus and IL-1RN*2
(alone or in combination) and risk for future cardiovascular events (CVE). The hazard ratio (HR)
for a CVE given positive CMV-serology and IL-1RN*2 was 1.07 (95% confidence interval (CI) 0.32–
3.72) in the fully adjusted model compared to seronegative CMV patients not carrying the IL-
1RN*2 allele. In this prospective cohort study involving 300 patients with angiographically defined
CAD at baseline, homozygousity for allele 2 of the IL-1 RA and seropositivity to CMV alone and in
combination were not associated with an increased risk for cardiovascular events during follow-up;
in addition, combination of the CMV-seropositivity and IL-1RN*2 allele were not associated with
a proinflammatory response
Conclusion: Our study suggests that seropositivity to CMV and IL-1RA*2 genotype alone or in
combination might not be a strong risk factor for recurrent cardiovascular events in patients with
manifest CAD, and is not associated with levels of established inflammatory markers.
Background
A chronic, low-grade inflammatory response plays a key
role in atherosclerosis [1]. It has been suggested that
chronic inflammatory stimuli originating from infectious
Published: 20 May 2005
BMC Cardiovascular Disorders 2005, 5:10 doi:10.1186/1471-2261-5-10
Received: 16 September 2004
Accepted: 20 May 2005
This article is available from: http://www.biomedcentral.com/1471-2261/5/10
© 2005 Rothenbacher et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2005, 5:10 http://www.biomedcentral.com/1471-2261/5/10
Page 2 of 7
(page number not for citation purposes)
agents may contribute to this low-grade inflammation
and thus, might play a causal role in atherogenesis and
disease progression in patients with manifest chronic cor-
onary artery disease (CAD) [2]. The cytomegalovirus
(CMV) infection has been discussed as potential culprit to
cause atherosclerosis and especially to be involved in res-
tenosis [3] as it, if once acquired, persists life long and
may undergo periodic reactivation from latency [4].
Genes involved in the inflammatory response, such as the
interleukin-1 receptor gene, which is polymorphic in
nature, might be important in determining the response
profile in patients with chronic inflammatory stimuli [5].
This gene is located on chromosome 2 in close prximity to
genes coding for IL-1α  and IL-1β . The main role of the IL-
1 system is to mediate the early inflammatory reactions
for protection against many different stimuli ranging from
microbial colonization, infections, to malignant transfor-
mation. IL-1RA levels typically increases during the course
of an inflammatory event so that an induced inflamma-
tion gets terminated. As persons homozygous for the
allele 2 of the interleukin 1 receptor antagonist (IL-1RA)
gene (Il-1RN*2) show a more prolonged and more severe
immune response compared to persons with other allele
constellations, subjects with the Il-1RN*2 allele and with
evidence of chronic infection might be at particular high
risk for cardiovascular events. However, data examining
the combination of both factors are lacking.
We investigated whether homozygousity for the allele 2 of
the IL-1RA and CMV-seropositivity might be associated
with an increased risk for the development of cardiovascu-
lar events in patients with prevalent CAD to determine its
prognostic value in secondary disease prevention in a pro-
spective cohort study and whether this constellation was
associated with various inflammatory response markers.
Methods
Study design and population
Baseline examination
Patients were recruited between October 1996 and
November 1997 and were part of a case-control study
investigating the role of infectious agents in primary CAD;
details were reported elsewhere [6]. Briefly, the patient
group consisted of 312 patients aged 40–68 years with
clinically stable CAD who underwent elective coronary
angiography in the Department of Cardiology at the Uni-
versity of Ulm Medical Centre during this period and who
had a coronary stenosis of ≥  50% of the luminal diameter
of at least one major coronary artery. Patients with diag-
nosis of CAD older than 2 years, patients with acute coro-
nary syndromes, and patients on anticoagulant therapy
within the previous four weeks were excluded from the
study.
At baseline, all study participants underwent a standard-
ized interview carried out by specially trained interview-
ers. Participation was voluntary and written informed
consent was obtained from each subject upon entry into
the study. The study was approved by the ethics commit-
tee of the University of Ulm.
Follow-up examination
A follow-up (FU) of all patients with CAD was conducted
between October 2000 and April 2001. A personal inter-
view was conducted in the medical clinic (96.5%) or – if
patients were not willing or able to follow the invitation –
by phone by the same trained medical staff. Cardiovascu-
lar events (CVE) were defined by assessing the first occur-
rence of the following events during FU: cardiovascular
death, nonfatal myocardial infarction, ischemic cerebrov-
ascular event, and the need for coronary revascularization.
All CVEs were validated by chart review.
Laboratory methods
Venous blood was drawn under standardized conditions
directly before diagnostic coronary angiography at the
baseline examination. A complete blood cell count was
done automatically by a Coulter STKS counter (Coulter,
Krefeld, Germany). The remaining blood was centrifuged
at 3,000 g for 10 minutes within 30 min after venipunc-
ture, immediately aliquoted and frozen at -70°C until fur-
ther analysis.
IgG antibodies against CMV were determined using a
commercially available ELISA (CMV-IgG-ELISA PKS,
medac, Wedel Germany) for the detection and quantita-
tive determination of human IgG to cytomegalovirus
according to the manufacturer's instructions (borderline
zone 0.35–0.45 U/ml, only n = 3 (1%) of the samples had
a borderline result).
IL-1RA gene polymorphisms were done by PCR as
described in a similar study (7). Subjects homozygous for
allele 2 of the IL-1RA gene (IL-1RN*2) were grouped
against all other alleles constellations in the statistical
analysis.
Additionally, the following markers of inflammation were
determined by ELISA: Interleukin-6 (IL-6), and Tumor
Necrosis Factor (TNF)-α  (Quantikine, R&;D Systems,
Wiesbaden, Germany), inter-cellular adhesion molecule
(ICAM)-1 (Diaclone, Besancon, France). In addition, C-
reactive protein (CRP) determinations were done by an
immunoradiometric assay (range 0.05–10 mg/L) cali-
brated with the WHO reference standard 85/506. Serum
amyloid A (SAA) was also determined by immunoneph-
elometry (Dade Behring, Marburg, Germany). All labora-
tory analyses were done in a blinded fashion.BMC Cardiovascular Disorders 2005, 5:10 http://www.biomedcentral.com/1471-2261/5/10
Page 3 of 7
(page number not for citation purposes)
Statistical analysis
Baseline demographic and clinical characteristics of cases
were compared in a descriptive way. The association of
anti-CMV IgG antibody titer (positive vs negative or bor-
derline [1%]) and of the IL-1RA gene polymorphisms (IL-
1RN*2 vs. others) with the occurrence of cardiovascular
events during follow-up was analyzed by Chi-square (χ 2)
statistics. If expected cell frequencies were < 5, Fisher's
Exact Test was used.
In addition the relation of CMV, of the IL-1RA gene poly-
morphisms and their combination with CVD events dur-
ing follow-up was assessed by the Kaplan-Meier method
and quantified by means of the log-rank test.
Multivariate Cox regression analysis was performed to
determine the hazard ratio (HR) and 95% confidence
intervals (CI) for future cardiovascular events taking
potential confounding factors into account (controlling
for age (years), gender, body mass index (BMI, kg/m2),
school education, cigarette smoking, alcohol consump-
tion, history of Myocardial infarction, history of hyperten-
sion, history of diabetes, statin intake, intake of aspirin,
and intake of diuretics). The proportional hazard assump-
tion were checked graphically. A general linear regression
method was employed to calculate gender and age
adjusted mean values (arithmetic, if skewed geometric)
associated with CMV-seropositivity and the IL-1RN*2
allele compared to all other constellations. All analyses
were carried out with the SAS statistical software package
(SAS Institute, Version 8, Cary, North Carolina: SAS Insti-
tute, Inc).
Results
In this prospective study a total of 300 (96.2%) out of 312
patients with a mean age of 57.9 years were followed for a
median of 38.2 months (maximum 53.8 months). Twelve
subjects could not be included in the follow-up as they
refused to participate or they moved out of Germany and
could not be contacted during follow-up. During the fol-
low-up, 11 fatal and 49 non-fatal CVE occurred (20%) (5
patients died of a non-cardiac cause). Among CAD
patients, who subsequently developed a non-fatal CVE,
four patients suffered a myocardial infarction, seven an
ischemic cerebrovascular event, and coronary revasculari-
zation was performed in 38 subjects.
Table one shows the main characteristics of the patients in
patients with (n = 60) and without (n = 240) a CVE during
follow-up. There were no statistically significant differ-
ences with respect to gender, age, mean body mass index,
alcohol consumption habits and smoking status, and his-
tory of dyslipidemia, hypertension, diabetes and prior
myocardial infarction. IN addition, coronary status and
history of percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG) at baseline was also
similar among the two groups.
Table two shows the prevalence of the IL-1RN*2 allele,
and the seroprevalence of CMV infection (results of the
quantitative CMV analysis were not available in 5
patients). 8.3% and 10.4% (p = 0.6) of the patients with
and without CVE respectively, were homozygous for the
IL-1RN*2 allele (known to be associated with a more
severe and prolonged inflammatory response).
Table 1: Baseline Characteristics of the Study Population (N = 300)
Patients With Cardiovascular 
Event (N = 60)
Patients Without Cardiovascular 
Event (N = 240)
p-value
Male, n (%) 51 (85) 206 (85.8) 0.9
Age (y) mean ± SD 57.5 ± 7.7 58.0 ± 7.2 0.7
Body mass index (kg/m2) mean ± SD 27.0 ± 5.7 27.2 ± 3.5 0.6
School education <10 yrs, n (%) 46 (76.7) 165 (68.7) 0.8
Daily alcohol consumption, n (%) 18 (30) 71 (29.6) 0.9
Smoking status:
Current, n (%) 1 (1.7) 25 (10.4)
Past, n (%) 41 (68.3) 158 (65.8)
Never, n (%) 18 (30) 57 (23.8) 0.07a
History of:
Dyslipidemia, n (%) 37 (61.7) 167 (69.6) 0.2
Hypertension, n (%) 36 (60) 138 (57.5) 0.7
Diabetes, n (%) 9 (15) 32 (13.3) 0.7
Prior myocardial infarction, n (%) 40 (66.7) 144 (60.3) 0.4
a = Fisher's Exact Test usedBMC Cardiovascular Disorders 2005, 5:10 http://www.biomedcentral.com/1471-2261/5/10
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Overall, 52.7% of the patients were seropositive for CMV,
and the distribution was similar in patients with and with-
out CVE during follow-up (50.9% and 53.2% respectively,
p = 0.7). There was also no difference in distribution
among the two groups if IL-1RA genotype and CMV-sero-
positivity were combined: the IL-1RN*2 allele and CMV-
seropositivity occurred in 5.1% of patients with CVE and
in 4.7% of patients without, respectively (p = 0.8).
Table 2: Prevalence of interleukin-1 receptor antagonist gene polymorphisms (IL-1RA) and serostatus of CMV and their combination 
in patients with and without cardiovascular events during follow-up
Patients with Cardiovascular Event 
(n = 60)




- othera 55 (91.7%) 215 (89.6%)
- Il-1RN*2 5 (8.3%) 25 (10.4%) 0.6
CMV-serostatusb
- negative 29 (49.2%) 110 (46.8%)
- positive 30 (50.9%) 125 (53.2%) 0.7
IL-1 RA and CMV serostatus
- IL-othera and CMV-negative 27 (45.8%) 96 (40.9%)
- IL-othera and CMV-positive 27 (45.8%) 114 (48.5%)
- Il-1RN*2 and CMV-negative 2 (3.4%) 14 (6.0%)
- Il-1RN*2 and CMV-positive 3 (5.1%) 11 (4.7%) 0.8c
a = all other alleles summarized (IL-1RN*4, IL-1RN*5, IL-1RN*3) except IL-RN*2
b = in 6 patients quantitative determination of IgG was not available
c = Fisher exact test
Table 3: Distribution of factors and relation to cardiovascular events during follow-up and partly and fully adjusted hazard ratios for 
cardiovascular events associated with Interleukin-1 receptor antagonist gene polymorphisms (IL-1RA) and serostatus of CMV
Factor CVD-events during follow-up, 
row % (ap-value)
bPartly-adjusted hazard ratio 
(95% confidence interval)
cFully-adjusted hazard ratio 
(95% confidence interval)
IL-1 RA
- otherd 20.4% 1reference 1reference
- Il-1RN*2 16.3% (0.73) 1.1 (0.80–1.66) 1.03 (0.60–1.76)
CMV-serostatus
- negative 20.7% 1reference 1reference
- positive 0.91 (0.55–1.52) 1.00 (0.59–1.72)
- positive, titre < median 16.7% 0.74 (0.38–1.43) 0.78 (0.40–1.54)
- positive titre ≥  median 22.1% (0.54) 1.12 (0.61–2.05) 1.32 (0.69–2.52)
IL-1 RA and CMV serostatus
- IL-otherd and CMV-negative 21.9% 1reference 1reference
- IL-otherd and CMV-positive 19.1% 0.86 (0.50–1.45) 0.94 (0.54–1.64)
- Il-1RN*2 and CMV-negative 12.5% 0.56 (0.13–2.36) 0.37 (0.08 – 1.67)
- Il-1RN*2 and CMV-positive 21.4% (0.83) 0.96 (0.32–3.43) 0.95 (0.27 – 3.38)
a = according to log-rank test
b = adjusted for age and gender
c = adjusted for age, gender, body mass index, school education, cigarette smoking, alcohol consumption, history of myocardial infarction, history of 
hypertension, history of diabetes, statin intake, intake of aspirin, intake of diuretics
d = all other allelesBMC Cardiovascular Disorders 2005, 5:10 http://www.biomedcentral.com/1471-2261/5/10
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Table three shows the results of the multivariate analysis.
Patients who had the IL-1RN*2 allele and patients serop-
ositive for CMV (the latter independently also from titer
values above the mean) showed no statistically significant
increased risk for subsequent fatal or non-fatal CVE, in
both, the partially as well as in the fully adjusted model.
In addition, if both factors were combined no increased
risk for CVE during follow-up was obtained (HR = 0.96
(95% CI 0.32–3.43) in the gender and age adjusted
model, and HR = 0.095 (95% CI 0.27–3.38) in the fully
adjusted model compared to CMV seronegative patients
not having the IL-1RN*2 allele).
In addition, we found no statistically significant differ-
ences for mean values (geometric means with exception of
ICAM-1 (arithmetic)) of CRP, SAA, Il-6, TNF-α , and
ICAM-1 after adjustment for age and gender when CMV-
seropositive patients with the IL-1RN*2 allele were com-
pared to others (table 4).
Discussion
In this prospective cohort study involving 300 patients
with angiographically defined CAD at baseline,
homozygousity for allele 2 of the IL-1 RA and seropositiv-
ity to CMV alone and in combination were not associated
with an increased risk for cardiovascular events during fol-
low-up; in addition, combination of the CMV-seropositiv-
ity and IL-1RN*2 allele were not associated with a
proinflammatory response. Therefore, these data do not
support the hypothesis that IL-1RN*2 genotype in combi-
nation with CMV seropositivity might be a strong risk fac-
tor for secondary cardiovascular events in patients with
already prevalent cardiovascular disease.
These results are in contrast to several reports in the liter-
ature suggesting a positive association between CMV sero-
positivity and progression of atherosclerosis [8].
However, the earlier evidence was mostly based on small
case-control studies with rather vague definitions of clini-
cal endpoints and with little or no adjustment for poten-
tial confounders. Meanwhile, several large prospective
seroepidemiological studies have shown no independent
association for CMV and coronary heart disease [9,10].
But clearly more carefully conducted prospective studies
in different patient populations are needed before definite
conclusions can be drawn [11,12].
Evidence for a possible influence of the IL-1 RA polymor-
phism on CAD has been inconclusive so far [5]. One study
reported a positive association with risk of CAD [13],
another reported an positive association for the IL1RN*2
genotype with risk of restenosis in patients with CAD, if
the population was restricted to a subgroup of patients
with single vessel disease [7]. We found no association of
CMV-serpositivity and IL1RN*2 allele with risk of CVE
during follow-up, even if both factors were combined.
It has been described that subjects with the IL1RN*2 gen-
otype might be more resistant against some infections [5].
Patients with the IL1RN*2 genotype indeed showed a
lower CMV-seroprevalence than others in our population
(55.2% vs. 46.6%), although this difference was not sta-
tistically significant.
Recently, it has been suggested that the detrimental effects
of CMV-seroprevalence may be limited to subjects with an
increased inflammatory response as characterized by high
levels of CRP [14,15] or high IL-6 levels [16]. We did not
find a positive association of CMV-seroprevalence with
the occurrence of CVE confined to subjects with high lev-
els (above the median) of IL-6 or CRP, although baseline
IL-6 and CRP values (the latter only tentatively) showed a
positive predictive association with the occurrence of car-
diovascular events during follow-up. However, this asso-
ciation was not modified by CMV-serostatus (data not
shown). As CMV-seroprevalence may be related to various
adverse factors associated with CAD itself, issues of con-
Table 4: Mean concentrationsa,b of various markers of inflammation in patients with Il-1RN*2 and positive CMV-serostatus compared 
to the others
IL-1 RA and CMV serostatus
- Il-1RN*2 and CMV-positive Others p-value
- CRP [mg/L] c 0.92 1.58 0.5
- SAA [mg/L] c 3.04 3.52 0.5
- Il-6 [pg/mL] c 2.19 2.43 0.6
- TNF-α  [pg/mL ] c 2.37 2.53 0.6
- ICAM-1 [ng/mL] 456.6 537.1 0.08
a = Adjusted for age and gender by general linear regression
b = Arithmetic or if skewed c geometric meansBMC Cardiovascular Disorders 2005, 5:10 http://www.biomedcentral.com/1471-2261/5/10
Page 6 of 7
(page number not for citation purposes)
founding have to be considered and may explain part of
the discrepancies in the literature so far. There may be
indeed a complicated interplay among established risk
factors and exposure to infectious agents as recently sug-
gested by our group [17].
When looking at the results of this study the following
limitations should be considered: seroprevalence may not
be a good marker for recurrent active infection with CMV,
or even more relevant in this context, reactivation of CMV;
cytomegalovirus-IgG does not diagnose active virus infec-
tion after primary infection. Furthermore, the current
study cannot exclude a weak association between sero-
prevalence to CMV and IL-1RN*2 genotype and risk of
CVE. However, the study had a power of 80 % to detect an
RR of at least 1.6 and more associated with CMV-seropos-
itivity alone, and an RR of 2.8 and more associated with
combined CMV-seropositivity and presence of the IL-
1RN*2 allele, respectively. In addition, lack of association
of the CMV-seropositivity and IL-1RN*2 allele with estab-
lished inflammatory marker levels, which play a key role
in atherogenesis, are further reassuring the essentially neg-
ative findings of this study.
Conclusion
Despite its limitations, our study suggests that seropositiv-
ity to CMV and IL-1RA*2 genotype alone or in combina-
tion might not be a strong risk factor for recurrent
cardiovascular events in patients with manifest CAD, and
is not associated with levels of established inflammatory
markers.
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